Literature DB >> 30723257

Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia.

Cécile Guénot1,2, Francis Lacombe3, Kaoutar Allou3, Florent Dumezy4, Jean Feuillard5, Franck Geneviève6, Estelle Guérin5, Julien Guy7, Marc Maynadié7, Orianne Wagner Ballon8, Claude Preudhomme4, André Baruchel9, Hervé Dombret10, Norbert Ifrah11, Marie C Béné12.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30723257     DOI： 10.1038/s41375-019-0393-0

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  5 in total

1.  MRD evaluation of AML in clinical practice: are we there yet?

Authors:  Sylvie D Freeman; Christopher S Hourigan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Minimal residual disease and stem cell transplantation outcomes.

Authors:  Jacqueline Cloos; Gert J Ossenkoppele; Richard Dillon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

3.  Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow.

Authors:  Colin D Godwin; Yi Zhou; Megan Othus; Mallette M Asmuth; Carole M Shaw; Kelda M Gardner; Brent L Wood; Roland B Walter; Elihu H Estey
Journal:  Blood       Date:  2021-01-28       Impact factor: 25.476

4.  Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.

Authors:  Wendelien Zeijlemaker; Angele Kelder; Jacqueline Cloos; Gerrit Jan Schuurhuis
Journal:  Curr Protoc Cytom       Date:  2019-12

5.  AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML.

Authors:  Diana Hanekamp; Jesse M Tettero; Gert J Ossenkoppele; Angèle Kelder; Jacqueline Cloos; Gerrit Jan Schuurhuis
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.